When AI Becomes a Self-Improving Strategic Asset The Battlefield That Exists Only in Code Imagine a commander who never ...

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Anthropic got the ball rolling on thinking about a pause on AI-builds-AI. I clarify the ins and outs. An AI Insider analysis and scoop.

Abstract: This brief proposes a recursive constrained sine second-order error promoting adaptive (RCSSOEPA) algorithm. Compared with classical recursive method, the ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. As TikTok users are experiencing a prolonged outage, many have been ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Birgitta Böckeler, Distinguished Engineer at ...

A Samsung AI researcher in Montreal has created a tiny AI model that punches far above its weight, challenging the industry’s focus on massive scale. Released this week, the 7-million-parameter Tiny ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Season 2, Episode 1 (February 14, 2025): This week, the GEN editors discussed some interesting and developing stories around AI, including an in-depth dialogue about what Recursion has been doing in ...

Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...